ANERGIX
Coulter Pharmaceutical, Inc.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 74198675 |
| Registration Number | 1995806 |
| Mark Drawing Code | 1000: Typeset: Word(s)/letter(s)/number(s) |
| Cancellation Code | 2 |
| Attorney Name | LORRAINE LINFORD |
| Attorney Docket Number | 210121.211 |
| Law Office Assigned | L50 |
| Employee Name | MICHOS, JOHN E |
Timeline
| 1991-08-27 | Application Filed |
| 1992-04-28 | Published for Opposition |
| 1996-03-22 | Date of First Use |
| 1996-08-20 | Trademark Registered |
| 2006-07-10 | Location: SCANNING ON DEMAND |
| 2007-05-26 | Cancelled |
| 2007-05-26 | Status: Dead/Cancelled |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  COULTER PHARMACEUTICAL, INC. |
| Name Change Details | NC41000001BY ASSIGNMENT, BY MERGER |
| Address | 1124 COLUMBIA ST., SUITE 200 SEATTLE DE 98104 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| Type Code | Type |
|---|---|
| GS0101 | biopharmaceutical compound used in treatment of specific autoimmune diseases |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| APPROVED FOR PUB - PRINCIPAL REGISTER | 1991-12-13 | 1 CNSA P: |
| NOTICE OF PUBLICATION | 1992-03-27 | 2 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 1992-04-28 | 3 PUBO A:Allowance for Publication |
| NOA MAILED - SOU REQUIRED FROM APPLICANT | 1993-03-23 | 4 NOAM O:Outgoing Correspondence |
| EXTENSION 1 FILED | 1993-09-16 | 5 EXT1 S: |
| EXTENSION 1 GRANTED | 1993-11-19 | 6 EX1G S: |
| EXTENSION 2 FILED | 1994-03-23 | 7 EXT2 S: |
| EXTENSION 2 GRANTED | 1994-05-13 | 8 EX2G S: |
| EXTENSION 3 FILED | 1994-09-16 | 9 EXT3 S: |
| EXTENSION 3 GRANTED | 1994-10-27 | 10 EX3G S: |
| EXTENSION 4 FILED | 1995-03-14 | 11 EXT4 S: |
| EXTENSION 4 GRANTED | 1995-04-21 | 12 EX4G S: |
| EXTENSION 5 FILED | 1995-09-20 | 13 EXT5 S: |
| EXTENSION 5 GRANTED | 1995-10-06 | 14 EX5G S: |
| USE AMENDMENT FILED | 1996-03-22 | 15 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 1996-06-21 | 16 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 1996-07-01 | 17 CNPR P: |
| REGISTERED-PRINCIPAL REGISTER | 1996-08-20 | 18 R.PR A:Allowance for Publication |
| PAPER RECEIVED | 2003-02-21 | 19 MAIL I:Incoming Correspondence |
| REGISTERED - SEC. 8 (6-YR) FILED | 2003-02-21 | 20 8.AF I:Incoming Correspondence |
| REGISTERED - SEC. 8 (6-YR) ACCEPTED | 2003-05-20 | 21 8.OK O:Outgoing Correspondence |
| CASE FILE IN TICRS | 2006-07-10 | 22 CFIT O:Outgoing Correspondence |
| CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | 2007-05-26 | 23 CAEX O:Outgoing Correspondence |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 ANERGIX 78216175 not registered Dead/Abandoned |
Corixa Corporation 2003-02-18 |
 ANERGIX 74198675 1995806 Dead/Cancelled |
COULTER PHARMACEUTICAL, INC. 1991-08-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 